信达医药宣布与礼来达成战略合作，在全球范围内开展肿瘤学和免疫学新药研发。

Group 1 - The core point of the article is that Sinopharm has announced a strategic collaboration with Eli Lilly to develop new drugs in oncology and immunology on a global scale [1] Group 2 - The partnership aims to leverage both companies' strengths in research and development to accelerate the discovery and commercialization of innovative therapies [1] - This collaboration signifies a growing trend in the pharmaceutical industry where companies are increasingly forming alliances to enhance their drug development capabilities [1] - The focus on oncology and immunology reflects the rising demand for advanced treatments in these therapeutic areas, which are critical for addressing significant health challenges [1]